title: Role and New Insights of Pirfenidone in Fibrotic Diseases.
abstract: Pirfenidone (PFD) is a non-peptide synthetic molecule issued as a broad-spectrum anti-fibrotic drug with the ability to decrease TGF-β1, TNF-α, PDGF and COL1A1 expression, which is highly related to prevent or remove excessive deposition of scar tissue in several organs. Basic and clinical evidence suggests that PFD may safely slow or inhibit the progressive fibrosis swelling after tissue injuries. Furthermore, a number of evidence suggests that this molecule will have positive effects in the treatment of other inflammatory diseases. This review contains current research in which PFD has been used as the treatment of several diseases, and focus mainly in the outcomes related to improve inflammation and fibrogenesis. Therefore, the main goal of this review is to focus on the novel findings of PFD efficacy rather than deepen in the chemical aspects of the molecule.
authors.affiliation: 1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico.
authors.forename: David Alejandro
authors.initials: DA
authors.lastname: Lopez-de la Mora
authors.affiliation: 1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico.
authors.forename: Cibeles
authors.initials: C
authors.lastname: Sanchez-Roque
authors.affiliation: 1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico.
authors.forename: Margarita
authors.initials: M
authors.lastname: Montoya-Buelna
authors.affiliation: 1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico.
authors.forename: Sergio
authors.initials: S
authors.lastname: Sanchez-Enriquez
authors.affiliation: 1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico.
authors.forename: Silvia
authors.initials: S
authors.lastname: Lucano-Landeros
authors.affiliation: 1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico. ; 2. Departamento de Ciencias de la Salud, CUValles, University of Guadalajara, Guadalajara - Ameca km. 45.5, Ameca (46600), Mexico.
authors.forename: Jose
authors.initials: J
authors.lastname: Macias-Barragan
authors.affiliation: 1. Institute for Molecular Biology and Gene Therapy, Department of Molecular Biology and Genomics, University of Guadalajara, Sierra Mojada St. 950, Guadalajara (44280), Mexico.
authors.forename: Juan
authors.initials: J
authors.lastname: Armendariz-Borunda
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D005123:Eye / Q000473:pathology; D005355:Fibrosis / Q000188:drug therapy*; D006801:Humans; D007668:Kidney / Q000473:pathology; D008103:Liver Cirrhosis / Q000188:drug therapy; D009206:Myocardium / Q000473:pathology; D011658:Pulmonary Fibrosis / Q000188:drug therapy; D011728:Pyridones / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D011728:Pyridones; C093844:pirfenidone
keywords: Pirfenidone; fibrosis; idiopathic pulmonary fibrosis; inflammation